利巴韦林不同给药途径治疗手足口病回顾性分析

Retrospective Analysis of Treatment of Ribavirin for Hand-Foot-and-Mouth Disease

目的分析利巴韦林不同给药途径治疗手足口病的疗效,为患者提供最佳给药途径。方法回顾性分析2009-05～2011-12本院300例HFMD患儿,根据利巴韦林不同给药途径分成利巴韦林静滴组、利巴韦林分散片组和利巴韦林喷剂组,按手足口病控制指标,评价效果。结果静滴组临床症状和体征消退时间较分散片组和喷剂组明显缩短(P<0.05);并发症较分散片组和喷剂组增多(P>0.05);但总的治愈病程时间和疗效无统计学意义(P>0.05)。结论利巴韦林不同给药途径治疗HFMD的总体疗效无明显差别,可根据患者情况选择"个体化"给药途径。

Objective To explore the best administration way of ribavirin in the treatment of hand-foot-and-mouth disease （HFMD）. Methods Three hundred cases of the HFMD in children were sampled and divided into 3 categories in terms of the administration of ribavirin, namely infusion group, dispersible tablet group, and spray group. The effectiveness of the treatment was evaluated based on control indicators of the disease. Results The clinical signs and symptoms of infusion group alleviated sooner than those of other groups （ P 〈 0.05 ）. Conclusion The total effectiveness of ribavirin on HFMD has no significant difference between different way of administration, and personalization administration is highly recommended in clinic.